IL6 and serum lipopolysaccharide activity: A recent human experimental endotoxemia model showed that peak interleukin-6 (IL-6) levels were reduced by half in volunteers treated with CytoSorb 15 min after the start of a 3-h lipopolysaccharide challenge (2), but most controlled clinical studies have been negative (3, 4).